Navigation Links
Watson Launches Generic FORTAMET(R)
Date:4/19/2012

PARSIPPANY, N.J., April 19, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of FORTAMET® (metformin hydrochloride extended-release tablets) as part of an agreement with Shionogi, Inc. Watson began shipping the product today. FORTAMET® is indicated as an adjunct to diet and exercise to lower blood glucose for patients 17 years of age or older.

For the most recent twelve months ending February 28, 2012, FORTAMET® had combined brand and generic sales of approximately $82 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

FORTAMET® is a registered trademark of Shionogi, Inc.

CONTACTS:
Investors:
Patty Eisenhaur
(862) 261-8141

Media:
Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

 


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
2. Watson Confirms Favorable District Court Ruling in Generic Sanctura XR® Patent Suit
3. Watson Partners With March of Dimes to Help Fight Preterm Birth
4. Watson Confirms NIASPAN(R) Patent Challenge
5. Watson Confirms BYSTOLIC(R) Patent Challenge
6. Watson Launches Generic PROMETRIUM(R)
7. Watson to Present at the Barclays Capital 2012 Global Healthcare Conference
8. Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
9. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference
10. Watson to Present at the Citi 2012 Global Healthcare Conference
11. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2020)... ... ... The Safe Boating Campaign, a worldwide effort focused on responsible boating, reminds boaters ... the leading contributing factor in recreational boater deaths, according to the U.S. Coast Guard. ... for drinking and boating, and deadly accidents,” said Peg Phillips, executive director of the ...
(Date:6/23/2020)... ... June 23, 2020 , ... Draper today ... technology can be used to test an in vitro human lung model to ... a collaboration between Draper and the University of Massachusetts Medical ...
(Date:6/23/2020)... ... June 23, 2020 , ... Award-winning digital product design and development agency Very ... users, to build a COVID-19 map . The goal between both companies was ... easy-to-understand data and visuals on the current COVID-19 situation both globally and locally. ...
Breaking Medicine Technology:
(Date:6/24/2020)... ... June 24, 2020 , ... The world’s largest cell phone trade-in price ... which cell phones will be worth the most two years after purchase. , ... iPhone, Samsung, Google, Sony and LG - and compared their 2018 MSRP with their ...
(Date:6/24/2020)... , ... June 24, 2020 , ... ... frenectomies for those with lip ties and tongue ties as well as ... offers a collaborative approach to care with multispecialty teams including myofunctional therapists and ...
(Date:6/23/2020)... ... June 23, 2020 , ... Anesthesia ... patients and providers alike. The virus, which is primarily found in oral, nasal, ... through respiratory droplets, contact contamination, or by aerosols produced during aerosol-generating procedures (AGPs). ...
(Date:6/23/2020)... LAUDERDALE, Fla. (PRWEB) , ... ... ... Health Partners , an expert in increasing revenue for hospitals and specialty ... Flywire , a high-growth vertical payments company. , The partnership will ...
(Date:6/23/2020)... ... June 22, 2020 , ... ... and renovation projects in 11 categories this year: 55+, Active Adult, Affordable, ... Skilled Nursing/Post-Acute Care and Standalone Memory Care. , “Particularly in light ...
Breaking Medicine News(10 mins):